From the King's College London British Heart Foundation Centre, Cardiovascular Division, Department of Clinical Pharmacology, London, UK (S.A.O., H.F., A.N., J.H., B.J., P.C., A.J.W.); Division of Women's Health, Women's Health Academic Centre, King's College London and King's Health Partners, London, UK (K.D.T., P.T.); Department of Anaesthetics (A.N.), and Biomedical Research Centre (S.A.O., H.F., A.N., J.H., B.J., P.C., A.W.), Guy's & St. Thomas' NHS Foundation Trust, London, UK.
Circulation. 2015 Jan 27;131(4):381-9; discussion 389. doi: 10.1161/CIRCULATIONAHA.114.009554. Epub 2014 Dec 22.
Inorganic nitrite dilates small resistance arterioles via hypoxia-facilitated reduction to vasodilating nitric oxide. The effects of nitrite in human conduit arteries have not been investigated. In contrast to nitrite, organic nitrates are established selective dilators of conduit arteries.
We examined the effects of local and systemic administration of sodium nitrite on the radial artery (a muscular conduit artery), forearm resistance vessels (forearm blood flow), and systemic hemodynamics in healthy male volunteers (n=43). Intrabrachial sodium nitrite (8.7 μmol/min) increased radial artery diameter by a median of 28.0% (25th and 75th percentiles, 25.7% and 40.1%; P<0.001). Nitrite (0.087-87 μmol/min) displayed conduit artery selectivity similar to that of glyceryl trinitrate (0.013-4.4 nmol/min) over resistance arterioles. Nitrite dose-dependently increased local cGMP production at the dose of 2.6 μmol/min by 1.1 pmol·min(-1)·100 mL(-1) tissue (95% confidence interval, 0.5-1.8). Nitrite-induced radial artery dilation was enhanced by administration of acetazolamide (oral or intra-arterial) and oral raloxifene (P=0.0248, P<0.0001, and P=0.0006, respectively) but was inhibited under hypoxia (P<0.0001) and hyperoxia (P=0.0006) compared with normoxia. Systemic intravenous administration of sodium nitrite (8.7 μmol/min) dilated the radial artery by 10.7% (95% confidence interval, 6.8-14.7) and reduced central systolic blood pressure by 11.6 mm Hg (95% confidence interval, 2.4-20.7), augmentation index, and pulse wave velocity without changing peripheral blood pressure.
Nitrite selectively dilates conduit arteries at supraphysiological and near-physiological concentrations via a normoxia-dependent mechanism that is associated with cGMP production and is enhanced by acetazolamide and raloxifene. The selective central blood pressure-lowering effects of nitrite have therapeutic potential to reduce cardiovascular events.
无机亚硝酸盐通过缺氧促进的还原作用舒张小阻力动脉,产生血管舒张作用的一氧化氮。亚硝酸盐在人体输送动脉中的作用尚未得到研究。与亚硝酸盐不同,有机硝酸盐是输送动脉的既定选择性舒张剂。
我们在健康男性志愿者(n=43)中检查了局部和全身给予亚硝酸钠对桡动脉(肌性输送动脉)、前臂阻力血管(前臂血流)和全身血液动力学的影响。臂内亚硝酸钠(8.7μmol/min)使桡动脉直径中位数增加 28.0%(25%和 75%分位数,25.7%和 40.1%;P<0.001)。亚硝酸盐(0.087-87μmol/min)对阻力小动脉的输送动脉选择性与甘油三硝酸酯(0.013-4.4nmol/min)相似。亚硝酸盐剂量依赖性地增加局部 cGMP 生成,在 2.6μmol/min 剂量下增加 1.1pmol·min(-1)·100mL(-1)组织(95%置信区间,0.5-1.8)。乙酰唑胺(口服或动脉内)和口服雷洛昔芬分别增强亚硝酸盐诱导的桡动脉扩张(P=0.0248,P<0.0001 和 P=0.0006),但在低氧(P<0.0001)和高氧(P=0.0006)下与常氧相比受到抑制。全身静脉内给予亚硝酸钠(8.7μmol/min)使桡动脉扩张 10.7%(95%置信区间,6.8-14.7),降低中心收缩压 11.6mmHg(95%置信区间,2.4-20.7),增加指数和脉搏波速度,而不改变外周血压。
亚硝酸盐以依赖于正常氧合的机制选择性地在超生理和近生理浓度下舒张输送动脉,该机制与 cGMP 产生有关,并被乙酰唑胺和雷洛昔芬增强。亚硝酸盐选择性降低中心血压的作用具有降低心血管事件的治疗潜力。